Maravai LifeSciences (MRVI) Tops Q4 EPS by 2c, beats on guidance

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $74.1 million versus the consensus estimate of $64.57 million.

GUIDANCE:

Maravai LifeSciences sees FY2024 revenue of $265-285 million, versus the consensus of $261 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
• Commercial Metals (CMC) Tops Q3 EPS by 3c, Beats on Revenue
• Barclays sees global expansion intact, warns against market complacency